SRPT
Undervalued by 20.3% based on the discounted cash flow analysis.
Market cap | $10.94 Billion |
---|---|
Enterprise Value | $10.51 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-5.8 |
Beta | 0.0 |
Outstanding Shares | 93,900,000 |
Avg 30 Day Volume | 602,166 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -20.42 |
---|---|
PEG | 14.4 |
Price to Sales | 9.8 |
Price to Book Ratio | 14.15 |
Enterprise Value to Revenue | 8.45 |
Enterprise Value to EBIT | -39.23 |
Enterprise Value to Net Income | -20 |
Total Debt to Enterprise | 0.12 |
Debt to Equity | 1.44 |
No data
No data
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...